TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33645243

Group type: EXPERIMENTAL
Intervention: Ribociclib plus endocrine therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus endocrine therapy
Number of subjects: 0
Study: 35682213

Group type: EXPERIMENTAL
Intervention: IPC (3 cycles of 5‐min compression/5‐min reperfusion at 15 mmHg above systolic blood pressure)
Number of subjects: 16
Study: 34911068

Group type: EXPERIMENTAL
Intervention: IV analgesics and intrapapillary local anesthetic infiltrations
Number of subjects: 88

Group type: COMPARATOR
Intervention: IV analgesics
Number of subjects: 88
Study: 35085151

Group type: EXPERIMENTAL
Intervention: Online one-day workshop based on cognitive behavioral therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 33197403

Group type: EXPERIMENTAL
Intervention: PSV plus sigh (increase in airway pressure to 30 cm H2O for 3 s once per minute)
Number of subjects: 258

Group type: COMPARATOR
Intervention: PSV alone (no-sigh group)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: PSV plus sigh
Number of subjects: 258
Study: 32005058

Group type: EXPERIMENTAL
Intervention: parecoxib
Number of subjects: 185
Study: 34875052

Group type: EXPERIMENTAL
Intervention: Improved water supply, sanitation and hygiene, and improved infant feeding
Number of subjects: 5280

Group type: EXPERIMENTAL
Intervention: Preterm infants
Number of subjects: 5280

Group type: EXPERIMENTAL
Intervention: Preterm births
Number of subjects: 5280
Study: 34016168

Group type: EXPERIMENTAL
Intervention: CRMRF activated group
Number of subjects: 80

Group type: COMPARATOR
Intervention: CRMRF deactivated group
Number of subjects: 80
Study: 32007138

Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg orally twice daily plus trametinib 2 mg orally once daily
Number of subjects: 870

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib
Number of subjects: 870
Study: 35477434

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 2
Study: 34254280

Group type: EXPERIMENTAL
Intervention: 100 IU hCG/day
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 34809626

Group type: EXPERIMENTAL
Intervention: MyDiabetesPlan
Number of subjects: 213

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 213
Study: 34009274

Group type: EXPERIMENTAL
Intervention: CTLA‐4Ig (abatacept, n=17)
Number of subjects: 60

Group type: COMPARATOR
Intervention: anti‐IL6 receptor (tocilizumab, n=21)
Number of subjects: 60

Group type: COMPARATOR
Intervention: anti‐TNF (certolizumab‐pegol, n=22)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CTLA‐4Ig treatment
Number of subjects: 60
Study: 33856325

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fluid management (UGFM) using respiratory change of the IVC diameter
Number of subjects: 202

Group type: COMPARATOR
Intervention: Usual-care strategy
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fluid management (UGFM)
Number of subjects: 202
Study: 35333346

Group type: EXPERIMENTAL
Intervention: Use of mifepristone
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Number of previous uterine aspirations
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Presence of minor clinical symptoms (slight vaginal bleeding or some abdominal cramps) at treatment start
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Prediction model
Number of subjects: 344
Study: 33371715

Group type: EXPERIMENTAL
Intervention: Perianal infiltration of tramadol
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Perianal infiltration of bupivacaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 90
Study: 33181849

Group type: EXPERIMENTAL
Intervention: Propolis chewing gum, chewed twice daily for at least twenty minutes for two weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propolis mouthwash, rinsed twice daily for one minute for two weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propolis chewing gum
Number of subjects: 60
Study: 36396331

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg/d
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 34886156

Group type: EXPERIMENTAL
Intervention: At-home stool collection kit with detailed verbal instruction
Number of subjects: 480
Study: 35190411

Group type: EXPERIMENTAL
Intervention: Culturally adapted 6-week pulmonary rehabilitation (PR) programme
Number of subjects: 0
Study: 34540787

Group type: EXPERIMENTAL
Intervention: Cool (pre-cooling with ice slurry ingestion and per-cooling with ice-vest)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (standard PPE without cooling)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cool
Number of subjects: 12
Study: 33759658

Group type: EXPERIMENTAL
Intervention: Short training of the hospital staff aimed at improving the management of patients with cognitive impairment
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 68
Study: 33310380

Group type: EXPERIMENTAL
Intervention: Internal attentional focus group (n = 71)
Number of subjects: 138

Group type: COMPARATOR
Intervention: External attentional focus group (n = 67)
Number of subjects: 138
Study: 32452659

Group type: EXPERIMENTAL
Intervention: Clopidogrel hydrogen sulfate tablets (75 mg) under fed conditions
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Clopidogrel hydrogen sulfate tablets (75 mg) under fasted conditions
Number of subjects: 132

Group type: COMPARATOR
Intervention: Reference formulation (Plavix)
Number of subjects: 132
Study: 35717522

Group type: EXPERIMENTAL
Intervention: BCG plus levofloxacin
Number of subjects: 106

Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 106
Study: 33397322

Group type: EXPERIMENTAL
Intervention: Capture-recapture method using data from National Nosocomial Infection Surveillance System (NNIS) and Health Information Management database (HIM)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Detection of SSIs post-discharge
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Identification of the most frequently detected bacterium
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Median time between detection of SSI and discharge
Number of subjects: 503
Study: 32724219

Group type: EXPERIMENTAL
Intervention: New sampling method for corneal nerve quantification
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Automated method for corneal nerve quantification
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard procedure for corneal nerve quantification
Number of subjects: 88
Study: 35395868

Group type: EXPERIMENTAL
Intervention: Laparoscopic radical hysterectomy
Number of subjects: 780

Group type: COMPARATOR
Intervention: Abdominal radical hysterectomy
Number of subjects: 780
Study: 33835230

Group type: EXPERIMENTAL
Intervention: Palonosetron (PALO) with dexamethasone
Number of subjects: 115

Group type: COMPARATOR
Intervention: Granisetron (GRA) with dexamethasone
Number of subjects: 115
Study: 32078078

Group type: EXPERIMENTAL
Intervention: HIV self-testing and partner-testing
Number of subjects: 272
Study: 35019995

Group type: EXPERIMENTAL
Intervention: Support from physicians
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Support from family and friends
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: More pain‐related disability days
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Worse work ability
Number of subjects: 690
Study: 34717692

Group type: EXPERIMENTAL
Intervention: Concurrent ibrutinib 560 mg continuously plus venetoclax ramp-up to 400 mg over 5 weeks
Number of subjects: 21
Study: 34323138

Group type: EXPERIMENTAL
Intervention: Self-affirmation inductions focusing on health values
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Self-affirmation inductions focusing on general values
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Essay-based self-affirmation inductions
Number of subjects: 1056

Group type: COMPARATOR
Intervention: Questionnaire-based self-affirmation inductions
Number of subjects: 1056
Study: 33497730

Group type: EXPERIMENTAL
Intervention: Superior Laser Peripheral Iridotomy (LPI)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Temporal or Nasal Laser Peripheral Iridotomy (LPI)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Laser Peripheral Iridotomy (LPI)
Number of subjects: 454
Study: 32636324

Group type: EXPERIMENTAL
Intervention: erenumab 70 mg
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: erenumab 140 mg
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: erenumab (dose change from 140 mg to 70 mg)
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: erenumab (dose change from 70 mg to 140 mg)
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: erenumab (overall efficacy)
Number of subjects: 955

Group type: COMPARATOR
Intervention: erenumab
Number of subjects: 955
Study: 35435082

Group type: EXPERIMENTAL
Intervention: CNN ResNet 18-based radiomics model
Number of subjects: 513
Study: 33198627

Group type: EXPERIMENTAL
Intervention: 60 primer pairs for non-redundant EST-SSRs
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 15 SSRs (10 sequence-verified and 5 unverified)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Dendrogram analysis of 34 individuals representing the seven L. radiata lines
Number of subjects: 7
Study: 35881774

Group type: EXPERIMENTAL
Intervention: AIM HI training
Number of subjects: 144
Study: 32698694

Group type: EXPERIMENTAL
Intervention: Tailored intervention visits (up to six visits over 30 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 35033048

Group type: EXPERIMENTAL
Intervention: Intervention consisting of six behavior change strategies and hardware provision (wash basin, bucket with lid, latrine training mat)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control arm (no specific intervention details provided)
Number of subjects: 74
Study: 34002560

Group type: EXPERIMENTAL
Intervention: Moxibustion combined with leflunomide tablets, applied at Sanyinjiao (SP 6), Shenshu (BL 23), Zusanli (ST 36) and ashi points, once every other day, three times a week for 8 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Leflunomide tablets taken orally, once a day for 8 weeks.
Number of subjects: 60
Study: 33413456

Group type: EXPERIMENTAL
Intervention: Meter 1 ‐ Precision Xtra
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Meter 2 ‐ Keto‐Mojo
Number of subjects: 13
Study: 616172358

Group type: EXPERIMENTAL
Intervention: Phrenic nerve neurostimulation using the remede device
Number of subjects: 3
Study: 36078289

Group type: EXPERIMENTAL
Intervention: Community-Integrated Intermediary Care (CIIC) intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study: 34237553

Group type: EXPERIMENTAL
Intervention: Animal Assisted Therapy (AAT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 53
Study: 32128512

Group type: EXPERIMENTAL
Intervention: Linear stapler technique (Group A)
Number of subjects: 41
Study: 34128766

Group type: EXPERIMENTAL
Intervention: Measles Containing Vaccines (MCVs)
Number of subjects: 548

Group type: COMPARATOR
Intervention: Unvaccinated
Number of subjects: 548
Study: 33053116

Group type: EXPERIMENTAL
Intervention: PBSC transplantation (PBSCT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: PE (plasma exchange)
Number of subjects: 60

Group type: COMPARATOR
Intervention: G‐CSF (granulocyte colony‐stimulating factor)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PBSCT (PBSC transplantation)
Number of subjects: 60
Study: 35818254

Group type: EXPERIMENTAL
Intervention: Dual-channel spine endoscopic lumbar discectomy
Number of subjects: 182

Group type: COMPARATOR
Intervention: Conventional lumbar discectomy
Number of subjects: 182
Study: 32642816

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 72

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 72
Study: 36011843

Group type: EXPERIMENTAL
Intervention: Multi-sector collaborative care for depression
Number of subjects: 980

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 980
Study: 32097252

Group type: EXPERIMENTAL
Intervention: ART delivered three-monthly in CARGs (3MC)
Number of subjects: 4800

Group type: EXPERIMENTAL
Intervention: ART delivered six-monthly in CARGs (6MC)
Number of subjects: 4800

Group type: COMPARATOR
Intervention: ART collected three-monthly at facility (3MF)
Number of subjects: 4800
Study: 36370907

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 50 mg with loading dose
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 50 mg without loading dose
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 30 mg
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 200/50 mg in extension period
Number of subjects: 364

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study: 33579240

Group type: EXPERIMENTAL
Intervention: 13-week behavioral lifestyle intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wait-listed control (self-guided strategies booklet)
Number of subjects: 60
Study: 32315810

Group type: EXPERIMENTAL
Intervention: HBV exposure (anti-HBc+)
Number of subjects: 3368

Group type: EXPERIMENTAL
Intervention: HBsAg+
Number of subjects: 3368

Group type: EXPERIMENTAL
Intervention: HBV vaccination-like profile (anti-HBs+ alone)
Number of subjects: 3368

Group type: EXPERIMENTAL
Intervention: Susceptibility to HBV
Number of subjects: 3368

Group type: EXPERIMENTAL
Intervention: HBV isolates classification
Number of subjects: 3368

Group type: EXPERIMENTAL
Intervention: HCV/HBV co-infection
Number of subjects: 3368

Group type: EXPERIMENTAL
Intervention: Treponema pallidum infection among HBV exposed prisoners
Number of subjects: 3368

Group type: EXPERIMENTAL
Intervention: Incidence of HBV
Number of subjects: 3368
Study: 35618567

Group type: EXPERIMENTAL
Intervention: ERBT
Number of subjects: 300

Group type: COMPARATOR
Intervention: cTURBT
Number of subjects: 300
Study: 33826641

Group type: EXPERIMENTAL
Intervention: Agent-based model with refined parameter estimation methods
Number of subjects: 0
Study: 36436883

Group type: EXPERIMENTAL
Intervention: BLI/WBT (Behavioral Lifestyle Intervention followed by Well-Being Therapy)
Number of subjects: 83

Group type: COMPARATOR
Intervention: BLI (Behavioral Lifestyle Intervention)
Number of subjects: 83
Study: 33579265

Group type: EXPERIMENTAL
Intervention: Atractylodes lancea extract (AL) at a single oral dose of 1000 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Atractylodes lancea extract (AL) at multiple dosing of 1000 mg for 21 days
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: β‐eudesmol
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Atractylodin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 35409816

Group type: EXPERIMENTAL
Intervention: E-learning-assisted educational videos and traditional techniques (Group B)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional teaching methods (Group A)
Number of subjects: 50
Study: 34130965

Group type: EXPERIMENTAL
Intervention: skills-based VR
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: distraction-based VR
Number of subjects: 360

Group type: COMPARATOR
Intervention: sham VR
Number of subjects: 360
Study: 32654111

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 32243274

Group type: EXPERIMENTAL
Intervention: 19 G EBUS needle
Number of subjects: 60

Group type: COMPARATOR
Intervention: 21 G EBUS needle
Number of subjects: 60
Study: 33231551

Group type: EXPERIMENTAL
Intervention: Steps2Health intervention with multimedia messaging service messages triggered by step counts
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Steps2Health intervention
Number of subjects: 78

Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 78
Study: 34898310

Group type: EXPERIMENTAL
Intervention: Bag-mask ventilation
Number of subjects: 138

Group type: COMPARATOR
Intervention: Apneic oxygenation
Number of subjects: 138
Study: 34254406

Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya Yoga (SKY)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Brisk walking
Number of subjects: 80
Study: 36380286

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia (CSEA)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Epidural analgesia (EA)
Number of subjects: 400
Study: 32084218

Group type: EXPERIMENTAL
Intervention: Tyrosine administration
Number of subjects: 0
Study: 34423649

Group type: EXPERIMENTAL
Intervention: Ticagrelor pooled (60 or 90 mg BID)
Number of subjects: 21162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21162
Study: 36403804

Group type: EXPERIMENTAL
Intervention: High status threat only
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: High acceptance threat only
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Combined threat
Number of subjects: 139

Group type: COMPARATOR
Intervention: Low evaluative threat
Number of subjects: 139
Study: 34656188

Group type: EXPERIMENTAL
Intervention: ebook + PCIT
Number of subjects: 178

Group type: COMPARATOR
Intervention: traditional PCIT
Number of subjects: 178
Study: 33579050

Group type: EXPERIMENTAL
Intervention: Individualized diet plan (Intervention Group)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Nutritional advice on healthy eating practices (Control Group)
Number of subjects: 34
Study: 32901611

Group type: EXPERIMENTAL
Intervention: Thulium laser transurethral vaporesection of the prostate (ThuVARP)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 410
Study: 34090780

Group type: EXPERIMENTAL
Intervention: Pregnant callers with Medicaid
Number of subjects: 28651

Group type: EXPERIMENTAL
Intervention: Non-pregnant callers with Medicaid
Number of subjects: 28651

Group type: EXPERIMENTAL
Intervention: Pregnant callers
Number of subjects: 28651

Group type: EXPERIMENTAL
Intervention: Non-pregnant callers
Number of subjects: 28651

Group type: EXPERIMENTAL
Intervention: All callers
Number of subjects: 28651
Study: 35709198

Group type: EXPERIMENTAL
Intervention: Virtual fishbowl teaching method
Number of subjects: 144

Group type: COMPARATOR
Intervention: Virtual seminar teaching method
Number of subjects: 144
Study: 34241780

Group type: EXPERIMENTAL
Intervention: Cemiplimab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 32187817

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting bioresorbable scaffold (BRS) implantation
Number of subjects: 176
Study: 32334527

Group type: EXPERIMENTAL
Intervention: Functional training for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Strength training for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Strength training
Number of subjects: 0
Study: 32085920

Group type: EXPERIMENTAL
Intervention: Phonetically studied vocal tasks recorded and analyzed by evaluators
Number of subjects: 33
Study: 32021219

Group type: EXPERIMENTAL
Intervention: Personal Construct Therapy (PCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study: 36058457

Group type: COMPARATOR
Intervention: Zilver (stenting without fasciotomy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ZilverFas (stenting with fasciotomy)
Number of subjects: 60
Study: 33595420

Group type: EXPERIMENTAL
Intervention: Succinylcholine
Number of subjects: 1230

Group type: COMPARATOR
Intervention: Rocuronium
Number of subjects: 1230

Group type: EXPERIMENTAL
Intervention: First attempt intubation failure
Number of subjects: 1230

Group type: COMPARATOR
Intervention: Successful first attempt intubation
Number of subjects: 1230

Group type: EXPERIMENTAL
Intervention: History of ear, nose and throat neoplasia
Number of subjects: 1230
Study: 32716330

Group type: EXPERIMENTAL
Intervention: Presence of feeding tube
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Presence of anemia
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Old age
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (no interruption)
Number of subjects: 6
Study: 35105560

Group type: EXPERIMENTAL
Intervention: Prenatal n‐3 long‐chain polyunsaturated fatty acids (n‐3 LCPUFA) supplementation
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: High‐dose vitamin D supplementation
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Early life exposures (infections, low grade inflammation, gut microbiome)
Number of subjects: 700
Study: 32747190

Group type: EXPERIMENTAL
Intervention: Concurrent treatment with pemetrexed plus cisplatin along with EGFR-TKI
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sequential treatment with EGFR-TKI followed by chemotherapy after progression
Number of subjects: 99
Study: 32490650

Group type: EXPERIMENTAL
Intervention: VAH + CAP + SSLF (Group 2)
Number of subjects: 150

Group type: COMPARATOR
Intervention: VAH + CAP (Group 1)
Number of subjects: 150
Study: 36104806

Group type: EXPERIMENTAL
Intervention: MPFLr combined with TTT
Number of subjects: 99

Group type: COMPARATOR
Intervention: Isolated MPFLr (iMPFLr)
Number of subjects: 99
Study: 33020134

Group type: EXPERIMENTAL
Intervention: Hypoglycemia (HypoEx) with blood glucose (BG)≤3.9 mmol/L
Number of subjects: 13

Group type: COMPARATOR
Intervention: Euglycemia (EuEx) with BG≥4.0, BG≤10.0 mmol/L
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Hypoglycemia (HypoEx)
Number of subjects: 13
Study: 35726118

Group type: EXPERIMENTAL
Intervention: External-focus instruction during dual-task walking
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Internal-focus instruction during dual-task walking
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Internal-focus training for 6 weeks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: External-focus training for 6 weeks
Number of subjects: 62
Study: 32344105

Group type: EXPERIMENTAL
Intervention: noisy galvanic vestibular stimulation (nGVS)
Number of subjects: 26

Group type: COMPARATOR
Intervention: sham stimulation (control)
Number of subjects: 26
Study: 34990385

Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 3266

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 3266